Prohost Letter #380
Investors Concerns, Excitments and Expectations
On Friday, July 24, Regeneron (REGN) stock closed at $541.l85 DOWN $14.76. The reason for loss was good news announcing that the FDA approved its cholesterol-lowering drug Praluent! Before the unreasonable sell on good news phenomenon, Regeneron had scored a new all time high on proven accomplishments (Read articles posted in past Prohost Letters).
Whoever is trying to give the impression that the novel cholesterol-lowering drug will not be a blockbuster selling for billions of dollars is . . .